Abstract
Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two devastating diseases that are currently incurable. Epidemiological, clinical and pathological evidence has confirmed the co-existence of these two disorders. Moreover, there has been promising progress made in the identification of the pathological linkage between T2DM and AD in the last decade. Hence, developing common treatment strategies for these diseases is important. Currently, enzyme targeting is a potential strategy to cure many diseases. In this communication, we tried to summarize the single enzymetargeted therapeutic approach for the treatment of AD and T2DM. This field of research continues to be active and progressive in identifying many promising enzymes that are involved in both diseases. Based on this review article, we also believe that enzyme inhibition is a promising and reliable strategy for the treatment of many incurable diseases. In the future, we expect that the scientific community will be able to develop common enzyme inhibitors for the treatment of both AD and T2DM.
Keywords: Alzheimer’s disease, diabetes, enzymes, drug therapy, endocrine disorders.
CNS & Neurological Disorders - Drug Targets
Title:Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
Volume: 13 Issue: 2
Author(s): Nasimudeen R. Jabir, Mohammad A. Kamal, Adel Mohammad Abuzenadah, Siew Hua Gan, Mohammed Nabil Alama, Saleh S. Baeesa and Shams Tabrez
Affiliation:
Keywords: Alzheimer’s disease, diabetes, enzymes, drug therapy, endocrine disorders.
Abstract: Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two devastating diseases that are currently incurable. Epidemiological, clinical and pathological evidence has confirmed the co-existence of these two disorders. Moreover, there has been promising progress made in the identification of the pathological linkage between T2DM and AD in the last decade. Hence, developing common treatment strategies for these diseases is important. Currently, enzyme targeting is a potential strategy to cure many diseases. In this communication, we tried to summarize the single enzymetargeted therapeutic approach for the treatment of AD and T2DM. This field of research continues to be active and progressive in identifying many promising enzymes that are involved in both diseases. Based on this review article, we also believe that enzyme inhibition is a promising and reliable strategy for the treatment of many incurable diseases. In the future, we expect that the scientific community will be able to develop common enzyme inhibitors for the treatment of both AD and T2DM.
Export Options
About this article
Cite this article as:
Jabir R. Nasimudeen, Kamal A. Mohammad, Abuzenadah Mohammad Adel, Gan Hua Siew, Alama Nabil Mohammed, Baeesa S. Saleh and Tabrez Shams, Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting, CNS & Neurological Disorders - Drug Targets 2014; 13 (2) . https://dx.doi.org/10.2174/18715273113126660145
DOI https://dx.doi.org/10.2174/18715273113126660145 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Caffeine and Glucose Metabolism at Rest Period, During, and Post Exercise in Diabetes Mellitus: A Systematic Review
Current Nutrition & Food Science Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Emerging Potential of Citrus Flavanones as an Antioxidant in Diabetes and its Complications
Current Topics in Medicinal Chemistry Prenatal Stress Enhances Susceptibility to Allergic Diseases of Offspring
Endocrine, Metabolic & Immune Disorders - Drug Targets Perioperative Management of Obese Parturients
Current Women`s Health Reviews Smoking and Endothelial Progenitor Cells: A Revision of Literature
Current Pharmaceutical Design Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Intravenous Glycoprotein IIb / IIIa Antagonists: Their Benefits, Problems and Future Developments
Current Pharmaceutical Design Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Group VI Phospholipases A2: Homeostatic Phospholipases with Significant Potential as Targets for Novel Therapeutics
Current Drug Targets Incretin Based Therapies: Bone Protective Effects
Endocrine, Metabolic & Immune Disorders - Drug Targets COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews Effects of Thiazolidinediones on Coronary Artery Disease: Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Retinal Imaging: A New Tool for Studying Underlying Liability to Cardiovascular Disease in Schizophrenia
Current Psychiatry Reviews Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Effects of Lipid-Lowering Drugs on Adiponectin
Current Vascular Pharmacology Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design